Skip to content

Dr. Gearóid Tuohy

Research studies focusing on causes of severe sight impairment (SSI) certifications correlated to the number of clinical studies registered in the UK.

Researchers at the Eye Research Institute, Anglia Ruskin University, Cambridge, UK, have published a report highlighting a correlation between registered clinical studies on leading causes… Read More »Research studies focusing on causes of severe sight impairment (SSI) certifications correlated to the number of clinical studies registered in the UK.

Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial.  This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization. 

Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization. 

Researchers at University Hospital Zurich have reported a novel dual AAV strategy aimed to correct ABCA4 gene mutations for Stargardt disease (STGD1).  

Researchers at the Laboratory for Retinal Gene Therapy, Department of Ophthalmology, University Hospital Zurich, Switzerland, have reported a novel treatment approach aimed to expand the… Read More »Researchers at University Hospital Zurich have reported a novel dual AAV strategy aimed to correct ABCA4 gene mutations for Stargardt disease (STGD1).  

Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV

Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV